Merck to acquire Imago BioSciences for $1.35 bn
Acquisition expands Merck’s growing hematology portfolio
Acquisition expands Merck’s growing hematology portfolio
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Subscribe To Our Newsletter & Stay Updated